QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019

QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019

Background: Observational studies have suggested increased arrhythmic and cardiovascular risk with the combination use of hydroxychloroquine (HCQ) and azithromycin in patients with coronavirus disease 2019 (COVID-19). Objective: The arrhythmic safety profile of HCQ monotherapy, which remains under i...

Descripció completa

Dades bibliogràfiques
Autors principals: Arun R. Sridhar, MBBS, MPH, Neal A. Chatterjee, MD, MSc, Basil Saour, MD, Dan Nguyen, MD, Elizabeth A. Starnes, ARNP, Christine Johnston, MD, MPH, Margaret L. Green, MD, MPH, Gregory A. Roth, MD, Jeanne E. Poole, MD, FHRS
Format: Article
Idioma:English
Publicat: Elsevier 2020-08-01
Col·lecció:Heart Rhythm O2
Matèries:
Coronavirus
Electrocardiogram
Hydroxychloroquine
QT interval
Ventricular arrhythmia
Accés en línia:http://www.sciencedirect.com/science/article/pii/S2666501820300751

Internet

http://www.sciencedirect.com/science/article/pii/S2666501820300751

Ítems similars